1
|
Miller EJ, Mays S, Baillie MT, Howard RB, Culver DG, Saindane M, Pruett ST, Holt JJ, Menaldino DS, Evers TJ, Reddy GP, Arrendale RF, Natchus MG, Petros JA, Liotta DC. Discovery of a Fluorinated Enigmol Analog with Enhanced in Vivo Pharmacokinetic and Anti-Tumor Properties. ACS Med Chem Lett 2016; 7:537-42. [PMID: 27190606 PMCID: PMC4867483 DOI: 10.1021/acsmedchemlett.6b00113] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Accepted: 03/21/2016] [Indexed: 11/30/2022] Open
Abstract
The orally bioavailable 1-deoxy-sphingosine analog, Enigmol, has demonstrated anticancer activity in numerous in vivo settings. However, as no Enigmol analog with enhanced potency in vitro has been identified, a new strategy to improve efficacy in vivo by increasing tumor uptake was adopted. Herein, synthesis and biological evaluation of two novel fluorinated Enigmol analogs, CF3-Enigmol and CF2-Enigmol, are reported. Each analog was equipotent to Enigmol in vitro, but achieved higher plasma and tissue levels than Enigmol in vivo. Although plasma and tissue exposures were anticipated to trend with fluorine content, CF2-Enigmol absorbed into tissue at strikingly higher concentrations than CF3-Enigmol. Using mouse xenograft models of prostate cancer, we also show that CF3-Enigmol underperformed Enigmol-mediated inhibition of tumor growth and elicited systemic toxicity. By contrast, CF2-Enigmol was not systemically toxic and demonstrated significantly enhanced antitumor activity as compared to Enigmol.
Collapse
Affiliation(s)
- Eric J. Miller
- Department
of Chemistry, Emory University, 1521 Dickey Drive NE, Atlanta, Georgia 30322, United States
| | - Suzanne
G. Mays
- Emory
University School of Medicine, Department
of Urology, 1365 Clifton
Road NE, Atlanta, Georgia 30322, United States
| | - Mark T. Baillie
- Department
of Chemistry, Emory University, 1521 Dickey Drive NE, Atlanta, Georgia 30322, United States
| | - Randy B. Howard
- Emory
Institute for Drug Development (EIDD), 954 Gatewood Road NE, Atlanta, Georgia 30329, United States
| | - Deborah G. Culver
- Emory
Institute for Drug Development (EIDD), 954 Gatewood Road NE, Atlanta, Georgia 30329, United States
| | - Manohar Saindane
- Emory
Institute for Drug Development (EIDD), 954 Gatewood Road NE, Atlanta, Georgia 30329, United States
| | - Sarah T. Pruett
- Yerkes
National Primate Research Center, Biomarkers Core Laboratory, Emory University, 954 Gatewood Road NE, Atlanta, Georgia 30329, United
States
| | - Jason J. Holt
- Department
of Chemistry, Emory University, 1521 Dickey Drive NE, Atlanta, Georgia 30322, United States
| | - David S. Menaldino
- Department
of Chemistry, Emory University, 1521 Dickey Drive NE, Atlanta, Georgia 30322, United States
| | - Taylor J. Evers
- Emory
Institute for Drug Development (EIDD), 954 Gatewood Road NE, Atlanta, Georgia 30329, United States
| | - G. Prabhakar Reddy
- Emory
Institute for Drug Development (EIDD), 954 Gatewood Road NE, Atlanta, Georgia 30329, United States
| | - Richard F. Arrendale
- Emory
Institute for Drug Development (EIDD), 954 Gatewood Road NE, Atlanta, Georgia 30329, United States
| | - Michael G. Natchus
- Emory
Institute for Drug Development (EIDD), 954 Gatewood Road NE, Atlanta, Georgia 30329, United States
| | - John A. Petros
- Emory
University School of Medicine, Department
of Urology, 1365 Clifton
Road NE, Atlanta, Georgia 30322, United States
- Emory
University School of Medicine, Department
of Pathology and Laboratory Medicine, 1364 Clifton Road NE, Atlanta, Georgia 30322, United
States
- Winship Cancer
Institute, Emory University, 1365 Clifton Road NE, Atlanta, Georgia 30322, United States
- Atlanta Veterans
Affairs Medical Center, Atlanta, Georgia 30033, United
States
| | - Dennis C. Liotta
- Department
of Chemistry, Emory University, 1521 Dickey Drive NE, Atlanta, Georgia 30322, United States
| |
Collapse
|
2
|
Mays SG, Baillie MT, Miller EJ, Bushnev AS, Pruett ST, Culver DG, Evers TJ, Gao J, Reddy GP, Natchus MG, Arrendale RF, Howard RB, Liotta DC, Petros JA. 330 FLUORINATION OF ENIGMOL IMPROVES TISSUE UPTAKE AND AFFECTS
IN VIVO
PROSTATE CANCER EFFICACY. J Urol 2013. [DOI: 10.1016/j.juro.2013.02.1715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
3
|
Guthrie DB, Stein DG, Liotta DC, Lockwood MA, Sayeed I, Atif F, Arrendale RF, Reddy GP, Evers TJ, Marengo JR, Howard RB, Culver DG, Natchus MG. Water-soluble progesterone analogues are effective, injectable treatments in animal models of traumatic brain injury. ACS Med Chem Lett 2012; 3:362-6. [PMID: 24900479 DOI: 10.1021/ml200303r] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2011] [Accepted: 03/15/2012] [Indexed: 01/04/2023] Open
Abstract
After more than 30 years of research and 30 failed clinical trials with as many different treatments, progesterone is the first agent to demonstrate robust clinical efficacy as a treatment for traumatic brain injuries. It is currently being investigated in two, independent phase III clinical trials in hospital settings; however, it presents a formidable solubility challenge that has so far prevented the identification of a formulation that would be suitable for emergency field response use or battlefield situations. Accordingly, we have designed and tested a novel series of water-soluble analogues that address this critical need. We report here the synthesis of C-20 oxime conjugates of progesterone as therapeutic agents for traumatic brain injuries with comparable efficacy in animal models of traumatic brain injury and improved solubility and pharmacokinetic profiles. Pharmacodynamic analysis reveals that a nonprogesterone steroidal analogue may be primarily responsible for the observed activity.
Collapse
Affiliation(s)
- David B. Guthrie
- Emory Institute for Drug Discovery
(EIDD), Emory University, 1515 Dickey Drive,
Atlanta, Georgia 30322, United States
| | - Donald G. Stein
- Emory University School of Medicine,
Department of Emergency Medicine, Emory University, Atlanta, Georgia 30322, United States
| | - Dennis C. Liotta
- Emory Institute for Drug Discovery
(EIDD), Emory University, 1515 Dickey Drive,
Atlanta, Georgia 30322, United States
- Department of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, Georgia
30322, United States
| | - Mark A. Lockwood
- Emory Institute for Drug Discovery
(EIDD), Emory University, 1515 Dickey Drive,
Atlanta, Georgia 30322, United States
| | - Iqbal Sayeed
- Emory University School of Medicine,
Department of Emergency Medicine, Emory University, Atlanta, Georgia 30322, United States
| | - Fahim Atif
- Emory University School of Medicine,
Department of Emergency Medicine, Emory University, Atlanta, Georgia 30322, United States
| | - Richard F. Arrendale
- Emory Institute for Drug Discovery
(EIDD), Emory University, 1515 Dickey Drive,
Atlanta, Georgia 30322, United States
| | - G. Prabhakar Reddy
- Emory Institute for Drug Discovery
(EIDD), Emory University, 1515 Dickey Drive,
Atlanta, Georgia 30322, United States
| | - Taylor J. Evers
- Emory Institute for Drug Discovery
(EIDD), Emory University, 1515 Dickey Drive,
Atlanta, Georgia 30322, United States
| | - Jose R. Marengo
- Emory Institute for Drug Discovery
(EIDD), Emory University, 1515 Dickey Drive,
Atlanta, Georgia 30322, United States
| | - Randy B. Howard
- Emory Institute for Drug Discovery
(EIDD), Emory University, 1515 Dickey Drive,
Atlanta, Georgia 30322, United States
| | - Deborah G. Culver
- Emory Institute for Drug Discovery
(EIDD), Emory University, 1515 Dickey Drive,
Atlanta, Georgia 30322, United States
| | - Michael G. Natchus
- Emory Institute for Drug Discovery
(EIDD), Emory University, 1515 Dickey Drive,
Atlanta, Georgia 30322, United States
| |
Collapse
|
4
|
Meyer EVS, Holt JJ, Girard KR, Ballie MT, Bushnev AS, Lapp S, Menaldino DS, Arrendale RF, Reddy GP, Evers TJ, Howard RB, Culver DG, Liotta DC, Galinski MR, Natchus MG. Sphingolipid analogues inhibit development of malaria parasites. ACS Med Chem Lett 2012; 3:43-7. [PMID: 24900369 DOI: 10.1021/ml2002136] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2011] [Accepted: 12/06/2011] [Indexed: 11/28/2022] Open
Abstract
Plasmodium-infected erythrocytes have been shown to employ sphingolipids from both endogenous metabolism as well as existing host pools. Therapeutic agents that limit these supplies have thus emerged as intriguing, mechanistically distinct putative targets for the treatment of malaria infections. In an initial screen of our library of sphingolipid pathway modulators for efficacy against two strains of the predominant human malaria species Plasmodium falciparum and Plasmodium knowlesi, a series of orally available, 1-deoxysphingoid bases were found to possess promising in vitro antimalarial activity. To better understand the structural requirements that are necessary for this observed activity, a second series of modified analogues were prepared and evaluated. Initial pharmacokinetic assessments of key analogues were investigated to evaluate plasma and red blood cell concentrations in vivo.
Collapse
Affiliation(s)
- Esmeralda V. S. Meyer
- Emory Vaccine Center and Yerkes
National Primate Research Center, Emory University, Atlanta, Georgia 30329, United States
| | - Jason J. Holt
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia
30322, United States
| | - Kathryn R. Girard
- Emory Vaccine Center and Yerkes
National Primate Research Center, Emory University, Atlanta, Georgia 30329, United States
| | - Mark T. Ballie
- Department of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, Georgia
30322, United States
| | - Anatoliy S. Bushnev
- Department of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, Georgia
30322, United States
| | - Stacey Lapp
- Emory Vaccine Center and Yerkes
National Primate Research Center, Emory University, Atlanta, Georgia 30329, United States
| | - David S. Menaldino
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia
30322, United States
| | - Richard F. Arrendale
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia
30322, United States
| | - G. Prabhakar Reddy
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia
30322, United States
| | - Taylor J. Evers
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia
30322, United States
| | - Randy B. Howard
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia
30322, United States
| | - Deborah G. Culver
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia
30322, United States
| | - Dennis C. Liotta
- Department of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, Georgia
30322, United States
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia
30322, United States
| | - Mary R. Galinski
- Emory Vaccine Center and Yerkes
National Primate Research Center, Emory University, Atlanta, Georgia 30329, United States
- Emory
University School of Medicine,
Department of Medicine, Division of Infectious Diseases, Emory University, Atlanta, Georgia 30322, United States
| | - Michael G. Natchus
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia
30322, United States
| |
Collapse
|
5
|
Garnier-Amblard EC, Mays SG, Arrendale RF, Baillie MT, Bushnev AS, Culver DG, Evers TJ, Holt JJ, Howard RB, Liebeskind LS, Menaldino DS, Natchus MG, Petros JA, Ramaraju H, Reddy GP, Liotta DC. Novel synthesis and biological evaluation of enigmols as therapeutic agents for treating prostate cancer. ACS Med Chem Lett 2011; 2:438-43. [PMID: 24900327 DOI: 10.1021/ml2000164] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2011] [Accepted: 03/09/2011] [Indexed: 12/22/2022] Open
Abstract
Enigmol is a synthetic, orally active 1-deoxysphingoid base analogue that has demonstrated promising activity against prostate cancer. In these studies, the pharmacologic roles of stereochemistry and N-methylation in the structure of enigmols were examined. A novel enantioselective synthesis of all four possible 2S-diastereoisomers of enigmol (2-aminooctadecane-3,5-diols) from l-alanine is reported, which features a Liebeskind-Srogl cross-coupling reaction between l-alanine thiol ester and (E)-pentadec-1-enylboronic acid as the key step. In vitro biological evaluation of the four enigmol diastereoisomers and 2S,3S,5S-N-methylenigmol against two prostate cancer cell lines (PC-3 and LNCaP) indicates that all but one diastereomer demonstrate potent oncolytic activity. In nude mouse xenograft models of human prostate cancer, enigmol was equally effective as standard prostate cancer therapies (androgen deprivation or docetaxel), and two of the enigmol diastereomers, 2S,3S,5R-enigmol and 2S,3R,5S-enigmol, also caused statistically significant inhibition of tumor growth. A pharmacokinetic profile of enigmol and N-methylenigmol is also presented.
Collapse
Affiliation(s)
- Ethel C. Garnier-Amblard
- Department of Chemistry, Emory University, 1521 Dickey Drive, Atlanta, Georgia 30322, United States
| | - Suzanne G. Mays
- School of Medicine, Department of Urology, Emory University, 1365 Clifton Road, NE, Atlanta, Georgia 30322, United States
| | - Richard F. Arrendale
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia 30322, United States
| | - Mark T. Baillie
- Department of Chemistry, Emory University, 1521 Dickey Drive, Atlanta, Georgia 30322, United States
| | - Anatoliy S. Bushnev
- Department of Chemistry, Emory University, 1521 Dickey Drive, Atlanta, Georgia 30322, United States
| | - Deborah G. Culver
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia 30322, United States
| | - Taylor J. Evers
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia 30322, United States
| | - Jason J. Holt
- Department of Chemistry, Emory University, 1521 Dickey Drive, Atlanta, Georgia 30322, United States
| | - Randy B. Howard
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia 30322, United States
| | - Lanny S. Liebeskind
- Department of Chemistry, Emory University, 1521 Dickey Drive, Atlanta, Georgia 30322, United States
| | - David S. Menaldino
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia 30322, United States
| | - Michael G. Natchus
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia 30322, United States
| | - John A. Petros
- School of Medicine, Department of Urology, Emory University, 1365 Clifton Road, NE, Atlanta, Georgia 30322, United States
- Atlanta Veterans Affairs Medical Center, Atlanta, Georgia 30033, United States
| | - Harsha Ramaraju
- School of Medicine, Department of Urology, Emory University, 1365 Clifton Road, NE, Atlanta, Georgia 30322, United States
| | - G. Prabhakar Reddy
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia 30322, United States
| | - Dennis C. Liotta
- Department of Chemistry, Emory University, 1521 Dickey Drive, Atlanta, Georgia 30322, United States
- Emory Institute for Drug Discovery (EIDD), 1515 Dickey Drive, Atlanta, Georgia 30322, United States
| |
Collapse
|
6
|
Price PW, McKinney EC, Wang Y, Sasser LE, Kandasamy MK, Matsuuchi L, Milcarek C, Deal RB, Culver DG, Meagher RB. Engineered cell surface expression of membrane immunoglobulin as a means to identify monoclonal antibody-secreting hybridomas. J Immunol Methods 2009; 343:28-41. [PMID: 19187782 DOI: 10.1016/j.jim.2009.01.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2008] [Revised: 01/11/2009] [Accepted: 01/13/2009] [Indexed: 11/26/2022]
Abstract
Monoclonal antibodies (mAbs) have proven to be effective biological reagents in the form of therapeutic drugs and diagnostics for many pathologies, as well as valuable research tools. Existing methods for isolating mAb-producing hybridomas are tedious and time consuming. Herein we describe a novel system in which mAb-secreting hybridoma cells were induced to co-express significant amounts of the membrane form of the secreted immunoglobulin (Ig) on their surfaces and are efficiently recovered by fluorescent activated cell sorting (FACS). Fusion of a novel myeloma parent, SP2ab, expressing transgenic Igalpha and Igbeta of the B-cell receptor complex (BCR) with spleen cells resulted in hybridomas demonstrating order of magnitude increases in BCR surface expression. Surface Ig levels correlated with transgenic Igalpha expression, and these cells also secreted normal levels of mAb. Hundreds of hybridoma lines producing mAbs specific for a variety of antigens were rapidly isolated as single cell-derived clones after FACS. Significant improvements using the Direct Selection of Hybridomas (DiSH) by FACS include reduced time and labor, improved capability of isolating positive hybridomas, and the ease of manipulating cloned cell lines relative to previously existing approaches that require Limiting Dilution Subcloning (LDS).
Collapse
|
7
|
Fischer LR, Culver DG, Davis AA, Tennant P, Wang M, Coleman M, Asress S, Adalbert R, Alexander GM, Glass JD. The WldS gene modestly prolongs survival in the SOD1G93A fALS mouse. Neurobiol Dis 2005; 19:293-300. [PMID: 15837585 DOI: 10.1016/j.nbd.2005.01.008] [Citation(s) in RCA: 88] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2004] [Revised: 01/04/2005] [Accepted: 01/12/2005] [Indexed: 11/19/2022] Open
Abstract
The "slow Wallerian degeneration" (Wld(S)) gene is neuroprotective in numerous models of axonal degeneration. Axonal degeneration is an early feature of disease progression in the SOD1G93A mouse, a widely used model of familial amyotrophic lateral sclerosis (fALS). We crossed the Wld(S) mouse with the SOD1G93A mouse to investigate whether the Wld(S) gene could prolong survival and modify neuropathology in these mice. SOD/Wld(S) mice showed levels of motor axon loss similar to that seen in SOD1G93A mice. The presence of the Wld(S) gene, however, modestly prolonged survival and delayed denervation at the neuromuscular junction. Prolonged survival was more prominent in female mice and did not depend on whether animals were heterozygous or homozygous for the Wld(S) gene. We also report that SOD1G93A mice show significant degeneration of sensory axons during the course of disease, supporting previous data from humans demonstrating that ALS is not purely a motor disorder.
Collapse
Affiliation(s)
- Lindsey R Fischer
- Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, Glass JD. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 2004; 185:232-40. [PMID: 14736504 DOI: 10.1016/j.expneurol.2003.10.004] [Citation(s) in RCA: 996] [Impact Index Per Article: 49.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The SOD1 mutant mouse is the most widely used model of human amyotrophic lateral sclerosis (ALS). To determine where and when the pathological changes of motor neuron disease begins, we performed a comprehensive spatiotemporal analysis of disease progression in SOD1(G93A) mice. Quantitative pathological analysis was performed in the same mice at multiple ages at neuromuscular junctions (NMJ), ventral roots, and spinal cord. In addition, a patient with sporadic ALS who died unexpectedly was examined at autopsy. Mice became clinically weak at 80 days and died at 131 +/- 5 days. At 47 days, 40% of end-plates were denervated whereas there was no evidence of ventral root or cell body loss. At 80 days, 60% of ventral root axons were lost but there was no loss of motor neurons. Motor neuron loss was well underway by 100 days. Microglial and astrocytic activation around motor neurons was not identified until after the onset of distal axon degeneration. Autopsy of the ALS patient demonstrated denervation and reinnervation changes in muscle but normal appearing motor neurons. We conclude that in this widely studied animal model of human ALS, and in this single human case, motor neuron pathology begins at the distal axon and proceeds in a "dying back" pattern.
Collapse
Affiliation(s)
- Lindsey R Fischer
- Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Wang MS, Davis AA, Culver DG, Wang Q, Powers JC, Glass JD. Calpain inhibition protects against Taxol-induced sensory neuropathy. ACTA ACUST UNITED AC 2004; 127:671-9. [PMID: 14761904 DOI: 10.1093/brain/awh078] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Taxol is a highly effective anticancer agent that causes peripheral neuropathy as its major toxic side effect. The neuropathy is characterized by degeneration of sensory axons that may be severe enough to be dose limiting. Axonal degeneration involves the activation of the calcium-activated proteases calpains, and here we tested whether systemic inhibition of calpains with the peptide alpha-ketoamide calpain inhibitor AK295 can reduce the clinical and pathological effects of Taxol in a rodent model of Taxol neuropathy. In mice with Taxol neuropathy, AK295 reduced the degree of axonal degeneration in sensory nerve roots, and improved clinical measures of neuropathy, including behavioural and electrophysiological function. These findings were consistent for both 3- and 6-week models of neuropathy. In vitro, Taxol caused activation of both calpains and caspases in PC12 cells. AK295 inhibited the activation of calpains but did not interfere with the antimitotic effects of Taxol on microtubules, nor did it inhibit caspase-mediated cell death. These data implicate calpains in the pathogenesis of Taxol neuropathy, and demonstrate that AK295 can prevent axonal degeneration and clinical neuropathy in mice. In addition, AK295 did not interfere with the primary antineoplastic effects of Taxol on microtubules and cell death, suggesting that systemic calpain inhibition may be a good strategy for preventing neuropathy in patients being treated with Taxol.
Collapse
Affiliation(s)
- Min Sheng Wang
- Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
| | | | | | | | | | | |
Collapse
|
10
|
Abstract
The WldS mouse is a unique mutant strain that demonstrates the remarkable phenotype of prolonged survival of transected axons ("slow Wallerian degeneration"). In these studies, we tested whether this neuroprotective phenotype extends to axonal degeneration seen in a progressive peripheral neuropathy. WldS and wild-type mice were intoxicated with the cancer chemotherapeutic agent paclitaxel (Taxol). The severity of the resultant sensory neuropathy was compared with behavioral, physiological, and pathological measures. WldS mice were resistant to paclitaxel neuropathy by all measures, and the resistance was because of protection against axonal degeneration. These studies demonstrate for the first time that the WldS mouse is more than a slow Wallerian degeneration phenotype, emphasizing the mechanistic link between Wallerian degeneration and peripheral neuropathy. Understanding how this mutant gene confers protection against axonal degeneration will provide important clues toward prevention of axonal degeneration in several human neurological disorders.
Collapse
Affiliation(s)
- Min Sheng Wang
- Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
| | | | | | | |
Collapse
|
11
|
Abstract
Peripheral nerve injury results in a series of events culminating in degradation of the axonal cytoskeleton (Wallerian degeneration). In the time period between axotomy and cytoskeletal degradation (24-48 h in rodents), there is calcium entry and activation of calpains within the axon. The precise timing of these events during this period is unknown. In the present study, antibodies were generated to three distinct peptide epitopes of m-calpain, and a fusion protein antibody was generated to the intrinsic calpain inhibitor calpastatin. These antibodies were used to measure changes in these proteins in mouse sciatic nerves during Wallerian degeneration. In sciatic nerve homogenates and cultured dorsal root ganglion (DRG) neurites, m-calpain protein was significantly reduced in transected nerves very early after nerve injury, long before axonal degeneration occurred. Levels of m-calpain protein remained low as compared to control nerves for the remainder of the 72-h time course. No changes in calpastatin protein were evident. Systemic treatment of animals with the protease inhibitor leupeptin partially prevented the rapid loss of calpain protein. Removal of calcium in DRG cultures had the same effect. These data indicate that m-calpain protein is lost very early after axonal injury, and likely reflect activation and degradation of this protein long before the cytoskeleton is degraded. Calpain activation may be an early event in a proteolytic cascade that is initiated by axonal injury and culminates with axonal degeneration.
Collapse
Affiliation(s)
- Jonathan D Glass
- Department of Neurology, Emory University School of Medicine, 1639 Pierce Drive, Suite 6000, Atlanta, GA 30322, USA.
| | | | | | | |
Collapse
|
12
|
Wang MS, Fang G, Culver DG, Davis AA, Rich MM, Glass JD. The WldS protein protects against axonal degeneration: a model of gene therapy for peripheral neuropathy. Ann Neurol 2001; 50:773-9. [PMID: 11761475 DOI: 10.1002/ana.10039] [Citation(s) in RCA: 80] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The WldS mouse is a spontaneous mutant that is characterized by the phenotype of delayed degeneration of transected nerves (slow Wallerian degeneration). Molecular genetic analysis identified a mutation in this animal that codes for a unique protein expressed in brain tissue of WldS mice. We asked whether the WldS phenotype, in addition to delaying axonal degeneration after axotomy, might provide neuroprotection against toxic neuropathy. In dorsal root ganglia (DRG) cultures, neurites from WldS transiently exposed to vincristine not only resisted axonal degeneration but resumed growth after withdrawal of the toxin. Neurites from wild type mice died rapidly and did not recover. To prove that the identified mutation and its protein product are responsible for the WldS phenotype, we used an adenoviral gene transfer system to deliver the WldS to rat DRG neurons. Rat neurons expressing the WldS protein were resistant to vincristine-induced axonal degeneration, confirming the functional significance of the identified gene mutation. These data provide evidence that the WldS protein can be neuroprotective against vincristine neuropathy, and possibly other disorders characterized by axonal degeneration. In addition, delivery of this gene to wild type cells can transfer the WldS phenotype, providing the possibility of "gene therapy" for peripheral neuropathy.
Collapse
Affiliation(s)
- M S Wang
- Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA
| | | | | | | | | | | |
Collapse
|
13
|
Abstract
Neurological diseases are frequently associated with axonal degeneration, which leads to dysfunction though separation of neurons from their targets. The mechanisms of axonal degeneration are largely unknown and in many cases are independent of those occurring within cell bodies in neurodegenerative disorders. The Wld(s) mouse mutant demonstrates the unique phenotype of resistance to axonal degeneration after axotomy (slow Wallerian degeneration), making it a powerful tool for studying mechanisms of axonal degeneration. We asked whether the Wld(s) mutation also provides resistance to axonal degeneration in a slowly progressing neuropathy. Using cultured dorsal root ganglion neurons we compared the course of axonal degeneration in response to exposure to the neurotoxin vincristine and found that Wld(s) neurites were relatively resistant to vincristine neuropathy. These findings suggest common pathophysiologic mechanisms between axotomy-induced Wallerian degeneration and toxic neuropathy. The implications are wide-ranging and are relevant to the pathophysiology of axonal degeneration seen in a wide spectrum of neurological diseases ranging from stroke and head trauma to spinal cord injury and peripheral neuropathy.
Collapse
Affiliation(s)
- M Wang
- Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
| | | | | | | |
Collapse
|
14
|
Wang MS, Wu Y, Culver DG, Glass JD. Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy. J Neuropathol Exp Neurol 2000; 59:599-606. [PMID: 10901231 DOI: 10.1093/jnen/59.7.599] [Citation(s) in RCA: 86] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Peripheral neuropathies and Wallerian degeneration share a number of pathological features; the most prominent of which is axonal degeneration. We asked whether common pathophysiologic mechanisms are involved in these 2 disorders by directly comparing in vitro models of axonal degeneration after axotomy or exposure to the neurotoxin vincristine. Embryonic rat dorsal root ganglia (DRG) were allowed to extend neurites for 5 days in culture, and then were either axotomized or exposed to 0.01 microM vincristine. Neurites universally degenerated by 3 days after axotomy or after 6 days of vincristine exposure. The neuroprotective effects of a low calcium environment or pharmacologic inhibition of the cysteine protease calpain were compared in these 2 models of axonal degeneration. Addition of EGTA or growth in zero-calcium media provided significant protection against axonal degeneration after either axotomy or vincristine exposure. Treatment with the experimental calpain inhibitor AK295 was equally protective in both models. Chronic exposure to AK295 was not toxic to the cultures. These data suggest that common mechanisms involving calcium and calpains are involved in both axotomy-induced and vincristine-induced axonal degeneration. In addition, calpain inhibition may provide a strategy for preventing axonal degeneration and preserving neurologic function in a variety of PNS and CNS disorders.
Collapse
Affiliation(s)
- M S Wang
- Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
| | | | | | | |
Collapse
|
15
|
Abstract
Identification of spectrin breakdown products (SBP) in tissues of the central nervous system (CNS) has been used to monitor calpain activity in models of neurodegeneration. We investigated the use of this technique in the peripheral nervous system (PNS) in order to use it as a marker of calpain-mediated proteolysis during axonal degeneration. Using in vitro methods for activation of calpains, we compared brains and sciatic nerves from rats for the presence of calpain-specific SBP. The 150-kDa SBP identified on western blots was demonstrated in brain and nerve homogenates subjected to membrane disruption in the presence of calcium. Incubation of tissues with recombinant m-calpain generated SBP in a dose-dependent fashion, and calpastatin inhibited the generation of SBP by either paradigm. In contrast to brain, sciatic nerves showed the presence of SBP even in noninjured tissues, suggesting a basal level of calpain activity in peripheral nerves. Time-course experiments showed that the generation of SBP in sciatic nerves correlated with the breakdown of axonal neurofilaments. SBP peaked within minutes after addition of m-calpain and disappeared in the homogenates before 1 h, indicating that identification of SBP is a transient phenomenon. These data provide a potential new way for studying axonal degeneration in both experimental and human neuropathies.
Collapse
Affiliation(s)
- M S Castejon
- Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
| | | | | |
Collapse
|
16
|
Abstract
The biological basis for the phenotype of delayed Wallerian degeneration in the WLDs mouse has yet to be elucidated, although it is known that the characteristic is intrinsic to the axon. Previous data suggested that nerves from the WLD(S) are relatively resistant to proteolytic degradation. We investigated the time-course of neurofilament degradation in response to addition of the calcium-activated protease m-calpain, comparing nerves from WLD(S) and wild-type mice. During 10 min of in vitro proteolysis, neurofilaments from the WLD(S) were consistently slower to degrade than were neurofilaments from wild-type mice. Direct comparisons were performed on Western blots, with statistically significant differences in neurofilament immunoreactivity at 2, 4, and 6 min of reaction time (p < 0.01). These findings suggest that the mutation leading to the WLD(S) phenotype may affect the proteolytic interaction between calpain and neurofilaments.
Collapse
Affiliation(s)
- B Bernier
- Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA
| | | | | | | |
Collapse
|